MOBIC Drug Patent Profile

When do Mobic patents expire, and when can generic versions of Mobic launch?

Mobic is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MOBIC is meloxicam. There is one drug master file entry for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mobic

A generic version of MOBIC was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for MOBIC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	2,542
Drug Prices:	Drug price information for MOBIC
What excipients (inactive ingredients) are in MOBIC?	MOBIC excipients list
DailyMed Link:	MOBIC at DailyMed

See drug prices for MOBIC

See drug sales revenues for MOBIC

US Patents and Regulatory Information for MOBIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-001	Apr 13, 2000		DISCN	Yes	No
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-002	Aug 23, 2000		DISCN	Yes	No

EU/EMA Drug Approvals for MOBIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22

Last updated: August 13, 2026

MOBIC (meloxicam) is a mature NSAID with limited branded economics and a large, price-sensitive generic market. Boehringer Ingelheim’s U.S. exclusivity ended years ago, generic meloxicam is widely available in tablets and oral suspension, and no biosimilar pathway applies. Current value is concentrated in generic volume, formulary access, retail prescriptions, and non-U.S. branded or licensed markets rather than in patent-protected revenue.

MOBIC (Meloxicam) Market Dynamics, Patent Status, and Financial Trajectory

What is MOBIC and how does meloxicam compete?

MOBIC is the brand name for meloxicam, a preferential cyclooxygenase-2 NSAID used to treat osteoarthritis and rheumatoid arthritis. The product is administered orally and is available primarily as 7.5 mg and 15 mg tablets. Meloxicam oral suspension is also approved in the United States for patients who cannot use tablets.[1]

MOBIC competes in a crowded NSAID market that includes:

• Celecoxib, sold as Celebrex and generic celecoxib
• Naproxen, including Aleve and prescription products
• Diclofenac, including topical and oral formulations
• Ibuprofen, including Advil, Motrin and generic products
• Etodolac, nabumetone and indomethacin

Meloxicam’s commercial positioning has historically depended on once-daily dosing, physician familiarity and perceived gastrointestinal tolerability relative to some older nonselective NSAIDs. Its clinical and commercial limitations include NSAID class warnings, cardiovascular risk, gastrointestinal bleeding risk, renal toxicity and restrictions in the perioperative coronary artery bypass graft setting.[1]

When did MOBIC lose exclusivity?

MOBIC lost meaningful U.S. market exclusivity after generic meloxicam products entered the market in the mid-2000s. The product is no longer an innovation-stage branded medicine in the United States.

The original product was approved by the FDA under NDA 020938. FDA records identify MOBIC as a conventional small-molecule drug, not a biologic. Generic manufacturers received ANDA approvals for meloxicam tablets and oral suspension after the relevant market and patent barriers expired or were successfully addressed.[2]

Commercial milestone	Approximate timing	Market effect
FDA approval of MOBIC	2000	Established meloxicam as a U.S. prescription NSAID
Initial branded market period	Early 2000s	Boehringer Ingelheim controlled branded sales
Generic meloxicam entry	Mid-2000s	Rapid price and share erosion
Mature generic market	2010s onward	Multiple suppliers and low unit pricing
Current U.S. status	2024	Generic-dominated, with no meaningful branded exclusivity

MOBIC’s U.S. commercial trajectory therefore follows the standard small-molecule lifecycle: branded launch, generic substitution, severe price compression and continuing prescription demand supported by the underlying disease burden.

What patents protect MOBIC and meloxicam?

No active U.S. patent estate appears to provide commercially meaningful exclusivity for the original MOBIC product. The Orange Book is the controlling FDA source for patents submitted for approved drug products, including listed patents, pediatric exclusivity and related regulatory protections.[3]

Patent and exclusivity profile

Protection category	Current position for MOBIC
Active compound patent exclusivity	Expired
Active formulation exclusivity	No meaningful U.S. branded barrier identified
Active method-of-use exclusivity	No material current barrier identified
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
U.S. Orange Book commercial barrier	None material for routine meloxicam products

Historic patents covering meloxicam’s compound, pharmaceutical compositions or use would have expired before the current generic market matured. Patent numbers are not commercially decisive today because generic manufacturers already compete across the principal U.S. dosage forms.

Patent risk remains more relevant for incremental products, including:

• Modified-release meloxicam
• Combination products
• New liquid or pediatric presentations
• Topical delivery systems
• Fixed-dose combinations with gastroprotective agents
• Novel administration devices
• New therapeutic indications

A new formulation could generate patent protection, but it would compete against a low-cost immediate-release generic base. That makes commercial differentiation difficult unless the product demonstrates a clear adherence, safety or dosing advantage.

What is the FDA regulatory status of MOBIC?

MOBIC is an FDA-approved prescription NSAID. The FDA-approved indications are osteoarthritis and rheumatoid arthritis in adults. The label includes a boxed warning for serious cardiovascular thrombotic events and serious gastrointestinal adverse events.[1]

FDA-approved dosage forms

Dosage form	Strengths	Commercial role
Tablet	7.5 mg, 15 mg	Core prescription market
Oral suspension	7.5 mg/5 mL	Smaller market, swallowing and dosing flexibility
Generic equivalents	Same principal strengths	Dominant U.S. supply

The product is administered once daily, with a maximum recommended daily dose of 15 mg for adults. Lower doses may be used in patients at higher risk of adverse events or in settings where clinicians seek the lowest effective NSAID exposure.[1]

MOBIC has no biosimilar risk because meloxicam is a chemically synthesized small molecule. The relevant competitive threat is generic substitution under the ANDA pathway, not the abbreviated 351(k) biosimilar pathway.

How many patents cover MOBIC in the Orange Book?

The practical answer is that no active Orange Book patent position materially protects the legacy MOBIC product in the United States. The original brand’s commercial protection has ended, and generic meloxicam products are approved across the core dosage forms.

Orange Book analysis should distinguish between:

1. Patents historically listed against the branded NDA.
2. Patents that remain unexpired on paper.
3. Patents that still block ANDA approval.
4. Patents that have commercial relevance after generic entry.

For MOBIC, the fourth category is the most important. The product is commercially unprotected in the U.S. generic market.

Which companies compete with MOBIC?

The market has two distinct competitive groups: generic meloxicam suppliers and branded or generic alternative NSAID manufacturers.

Generic meloxicam suppliers

Generic meloxicam has been marketed by multiple U.S. and international manufacturers, including large generic companies and contract suppliers. Availability varies by dosage form, distributor inventory, national market and payer contracts. The market is typically characterized by:

• Multiple ANDA holders
• Low barriers to tablet substitution
• High pharmacy purchasing leverage
• Periodic supplier consolidation
• Limited brand loyalty
• Price competition at the wholesaler and pharmacy level

The oral suspension segment has fewer suppliers than the tablet segment and may provide better pricing discipline. It remains a small portion of total meloxicam demand.

Competing NSAIDs

Celecoxib is the closest prescription competitor when physicians prioritize COX-2 selectivity. Naproxen competes on price, broad clinical familiarity and perceived cardiovascular positioning. Diclofenac remains important internationally and has a strong topical segment. Ibuprofen competes heavily in over-the-counter and lower-acuity use.

Product	Main competitive advantage	Main commercial weakness
Meloxicam	Once-daily dosing and broad generic availability	NSAID class risks and low pricing
Celecoxib	COX-2 selectivity and branded clinical positioning	Generic erosion and cardiovascular concerns
Naproxen	Low cost and broad familiarity	Twice-daily use and GI risk
Diclofenac	Strong international and topical presence	Cardiovascular and regulatory concerns
Ibuprofen	OTC access and low price	Shorter duration and frequent dosing

What is the financial trajectory of MOBIC?

MOBIC’s branded revenue trajectory is structurally negative after generic entry. Boehringer Ingelheim does not publicly disclose a standalone MOBIC revenue line in its corporate reporting, so the product cannot be valued from a reported brand-level sales figure.[4]

The financial pattern is clear:

1. Revenue expanded during the branded launch and adoption period.
2. Generic entry caused sharp unit-price declines.
3. Branded volume shifted to generic meloxicam.
4. Revenue became fragmented across multiple manufacturers.
5. Current economics depend on prescription volume, manufacturing cost and supply contracts rather than premium pricing.

Boehringer Ingelheim remains a major private pharmaceutical company, but its current financial performance is driven by newer products and franchises rather than legacy MOBIC sales. The company’s public reporting does not identify MOBIC as a material standalone growth driver.[4]

Revenue exposure

Revenue source	Current exposure
U.S. branded MOBIC	Minimal
U.S. generic meloxicam tablets	Distributed among several suppliers
U.S. generic oral suspension	Smaller but less commoditized
International meloxicam brands	Market-specific and variable
Licensing or authorized-brand economics	Not publicly disclosed as a material current contributor

A generic manufacturer can still generate meaningful aggregate sales from meloxicam because the molecule has persistent demand. However, net revenue per prescription is low, and profitability depends on scale, manufacturing efficiency, reliable supply and the ability to avoid excessive wholesaler discounts.

What generic entry risks exist for MOBIC?

Generic entry risk is no longer a future event for MOBIC. It is the central commercial condition of the product.

The main risks are:

• Further price erosion from additional suppliers
• Pharmacy and payer substitution away from any branded presentation
• Contract loss to lower-cost manufacturers
• Manufacturing disruptions that cause temporary shortages
• Reduced physician attention compared with newer analgesic products
• Clinical substitution to celecoxib, naproxen or topical NSAIDs
• Regulatory pressure related to NSAID safety labeling

The main remaining opportunities are operational rather than patent-driven. A supplier may improve economics through dependable inventory, vertically integrated manufacturing, differentiated suspension supply or participation in large payer and government contracts.

What formulations are protected by MOBIC patents?

The legacy tablet formulation has no meaningful current U.S. exclusivity barrier. Oral suspension products may have fewer suppliers, but limited competition does not necessarily indicate enforceable patent protection. Commercial scarcity can result from low demand, manufacturing complexity, limited ANDA participation or distributor economics.

Potentially defensible formulation concepts include:

• Taste-masked pediatric suspensions
• Lower-volume concentrated liquids
• Extended-release once-daily products
• Combination products with proton-pump inhibitors
• Fast-dissolving or alternative oral dosage forms
• Topical meloxicam delivery

These concepts would require separate FDA approvals and new intellectual property. They would not automatically restore protection to standard MOBIC tablets.

What patent litigation and Paragraph IV challenges affect MOBIC?

No current high-value U.S. patent litigation is central to the legacy MOBIC business. Paragraph IV litigation was most relevant during the original generic-entry period, when ANDA applicants could challenge listed patents and seek early market access.

The present market is post-litigation and post-exclusivity. Generic manufacturers compete under ordinary ANDA economics rather than through a pending Paragraph IV battle over the original MOBIC product.

A future Paragraph IV dispute could arise if a company develops a newly patented meloxicam formulation or combination. That dispute would concern the newer product’s patents, not the expired core meloxicam opportunity.

How does MOBIC compare with Celebrex and other NSAIDs?

MOBIC has a weaker brand position than Celebrex but a lower-cost position after genericization. The comparison is driven by clinical selection, payer policy and dosage convenience rather than patent protection.

Factor	MOBIC/meloxicam	Celebrex/celecoxib
Molecule type	Small-molecule NSAID	Small-molecule NSAID
U.S. exclusivity	Expired	Expired for original brand
Generic competition	Extensive	Extensive
Dosing	Usually once daily	Usually once or twice daily
Key market driver	Cost and familiarity	COX-2 positioning and clinical preference
Biosimilar risk	None	None
Patent value	Legacy protection expired	Legacy protection largely expired

MOBIC is better positioned where once-daily dosing and low acquisition cost matter. Celecoxib retains stronger differentiation in discussions of COX-2 selectivity, although its own generic availability has reduced brand economics.

What geographic markets remain relevant for MOBIC?

The United States is a mature generic market. International markets vary widely because of local patent histories, trademark ownership, regulatory approvals, reimbursement systems and physician prescribing patterns.

Meloxicam has commercial relevance in:

• Europe
• Latin America
• Asia-Pacific
• Central and Eastern Europe
• Selected Middle Eastern and African markets

Outside the United States, brand names, local manufacturers and distribution rights may differ. A country may have a branded meloxicam product even when the U.S. MOBIC brand has no commercial significance. Geographic analysis therefore requires country-level review of patent registers, regulatory approvals and tender activity.

How strong is the MOBIC patent estate?

The patent estate is weak for the original product and irrelevant to current U.S. generic entry. The strongest assets are operational:

• Established regulatory history
• Physician familiarity
• Broad generic availability
• Once-daily dosing
• Existing manufacturing know-how
• International registrations and trademarks

The weakest assets are:

• Brand pricing power
• U.S. patent exclusivity
• Product differentiation
• Ability to prevent substitution
• Standalone revenue visibility

Manufacturing barriers are modest for standard tablets. They are higher for oral suspension products because of formulation consistency, taste, stability, packaging and supply-chain requirements. Those barriers can support temporary commercial concentration but do not equal durable patent protection.

Key Takeaways

• MOBIC is the original branded meloxicam product from Boehringer Ingelheim.
• U.S. brand exclusivity ended in the mid-2000s, and generic meloxicam now dominates.
• No meaningful active U.S. patent barrier protects standard meloxicam tablets.
• The product has no biosimilar exposure because meloxicam is a small molecule.
• Boehringer does not report standalone MOBIC revenue, and the brand is not identified as a current growth driver.
• Generic profitability depends on volume, manufacturing cost, supply reliability and payer contracts.
• Oral suspension is less commoditized than tablets but remains a small market.
• Future value would require a differentiated formulation, combination product or new delivery system.
• The principal commercial risks are price erosion, substitution, supply disruption and NSAID safety restrictions.

FAQs About MOBIC Patent Expiration, Sales, and Generic Competition

Is MOBIC still sold as a branded drug?

MOBIC may remain available in selected markets, but U.S. prescribing is overwhelmingly supplied by generic meloxicam. Branded commercial importance is limited.

Does meloxicam have a 180-day generic exclusivity period today?

No current 180-day exclusivity period materially protects the mature meloxicam market. Any original first-filer exclusivity would have expired long ago.

Can a company launch a new patented meloxicam product?

Yes. A company can seek patents for a new formulation, combination, delivery system or method of use. The resulting protection would apply to the new product, not to standard meloxicam tablets.

Is meloxicam available over the counter in the United States?

No. Meloxicam is a prescription NSAID in the United States. Ibuprofen and naproxen are the principal widely available OTC NSAID competitors.

What would increase the value of a meloxicam manufacturer?

The most valuable commercial advantages would be low-cost production, reliable supply, a differentiated oral suspension, strong payer contracts or a clinically meaningful new formulation with enforceable intellectual property.

References

1. U.S. Food and Drug Administration. (2021). Mobic (meloxicam) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Mobic, NDA 020938.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Boehringer Ingelheim. (2024). Annual report and company financial information.